Clinical Case Reports (Apr 2021)

CPX‐351 (Vyxeos®) can cause severe rash in acute myeloid leukemia—A case report

  • Ruth M. Urbantat,
  • Valentin Popper,
  • Elisabeth Menschel,
  • Michael Pfeilstöcker,
  • Ernst Forjan,
  • Alexander Nader,
  • Catherine R. Sieghart,
  • Felix Keil,
  • Elisabeth Koller

DOI
https://doi.org/10.1002/ccr3.3909
Journal volume & issue
Vol. 9, no. 4
pp. 1933 – 1936

Abstract

Read online

Abstract CPX‐351, a promising new agent for patients with treatment‐related and secondary acute myeloid leukemia can lead to a severe whole‐body rash. Although severe side effects are rare, treatment should be carefully monitored at specialized centers.

Keywords